MedTrace Logo

CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study

NCT00876512 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2014-09-10

No results posted yet for this study

Summary

Dual antiplatelet therapy with aspirin and thienopyridines decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplatelet treatment, some of the patients undergoing PCI develop thrombotic stent occlusion, suggesting incomplete platelet inhibition due to thienopyridine resistance. The present study is designed in order to clarify the influence of CYP2C19 genetic polymorphism on the several biomarkers for platelet activation in Japanese patients treated with thienopyridines undergoing elective PCI.

Conditions

  • Stable Angina

Sponsors & Collaborators

  • Kumamoto University

    lead OTHER

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00876512 on ClinicalTrials.gov